Real-World Treatment Patterns and Survival Outcomes in Patients With Intermediate-Stage Hepatocellular Carcinoma.
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorSohag University
About this trial
The goal of this observational study is to learn about the different treatment options for intermediate-stage hepatocellular carcinoma. The main question it aims to answer is:
\- What are the survival outcomes among participants aged 18 or older who receive treatment for intermediate-stage hepatocellular carcinoma?
Eligibility criteria
Qualifiers
Aged ≥18 years.
Both sexes.
Diagnosis of hepatocellular carcinoma based on accepted radiologic or histologic criteria.
Classified as intermediate stage (BCLC-B) at time of decision for first-line treatment.
Disqualifiers
BCLC A, C, or D at diagnosis.
Prior curative therapy (resection, transplantation, curative ablation).
Missing essential data (imaging, liver function, treatment records).
Mixed HCC-cholangiocarcinoma.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
200 Participants
are grouped into 1 trial groupSponsors and collaborators
Sohag University
Lead sponsor
Sohag Oncology Center
Collaborator
Source ClinicalTrials.gov